Xeljanz receives marketing authorisation in EU to treat active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis Read more
Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis Read more